Smolders EJ - Search Results

1

An update on extravasation: basic knowledge for clinical pharmacists.

Smolders EJ, Benoist GE, Smit CCH, Ter Horst P. Smolders EJ, et al. Eur J Hosp Pharm. 2020 Apr 27;28(3):165-7. doi: 10.1136/ejhpharm-2019-002152. Online ahead of print. Eur J Hosp Pharm. 2020. PMID: 32341081 Free PMC article.

2

Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect.

Smolders EJ, Smit C, de Kanter C, Dofferhoff A, Arends JE, Brinkman K, Rijnders B, van der Valk M, Reiss P, Burger DM; ATHENA National HIV Observational Cohort. Smolders EJ, et al. HIV Med. 2018 Mar;19(3):216-226. doi: 10.1111/hiv.12570. Epub 2017 Dec 1. HIV Med. 2018. PMID: 29194939 Free article.

3

Cardiovascular Risk Management and Hepatitis C: Combining Drugs.

Smolders EJ, Ter Horst PJG, Wolters S, Burger DM. Smolders EJ, et al. Clin Pharmacokinet. 2019 May;58(5):565-592. doi: 10.1007/s40262-018-0710-1. Clin Pharmacokinet. 2019. PMID: 30259390 Free PMC article. Review.

4

Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update.

Smolders EJ, Jansen AME, Ter Horst PGJ, Rockstroh J, Back DJ, Burger DM. Smolders EJ, et al. Clin Pharmacokinet. 2019 Oct;58(10):1237-1263. doi: 10.1007/s40262-019-00774-0. Clin Pharmacokinet. 2019. PMID: 31114957 Free PMC article. Review.

5

Mercaptopurine and Metabolites in Breast Milk.

Ter Horst P, Smolders EJ, den Besten-Bertholee D. Ter Horst P, et al. Among authors: smolders ej. Breastfeed Med. 2020 Apr;15(4):277-279. doi: 10.1089/bfm.2019.0101. Epub 2019 Aug 16. Breastfeed Med. 2020. PMID: 31414890

6

The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview.

Giraud EL, Ferrier KRM, Lankheet NAG, Desar IME, Steeghs N, Beukema RJ, van Erp NP, Smolders EJ. Giraud EL, et al. Among authors: smolders ej. Lancet Oncol. 2022 Sep;23(9):e406-e415. doi: 10.1016/S1470-2045(22)00221-2. Lancet Oncol. 2022. PMID: 36055309 Review.

7

The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions.

Smolders EJ, Berden FA, de Kanter CT, Kievit W, Drenth JP, Burger DM. Smolders EJ, et al. United European Gastroenterol J. 2017 Aug;5(5):648-657. doi: 10.1177/2050640616678151. Epub 2016 Nov 4. United European Gastroenterol J. 2017. PMID: 28815028 Free PMC article.

8

Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment.

Smolders EJ, de Kanter CT, van Hoek B, Arends JE, Drenth JP, Burger DM. Smolders EJ, et al. Drug Saf. 2016 Jul;39(7):589-611. doi: 10.1007/s40264-016-0420-2. Drug Saf. 2016. PMID: 27098247 Free PMC article. Review.

9

Sixty milligram daclatasvir is the right dose for hepatitis C virus treatment in combination with etravirine and darunavir/ritonavir.

Smolders EJ, Kanter CT, Grintjes K, D'Avolio A, Di Perri G, van Crevel R, Drenth JP, Burger DM. Smolders EJ, et al. AIDS. 2016 Jun 1;30(9):1491-3. doi: 10.1097/QAD.0000000000001089. AIDS. 2016. PMID: 27167014 No abstract available.

10

Drug-Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications.

Smolders EJ, de Kanter CT, de Knegt RJ, van der Valk M, Drenth JP, Burger DM. Smolders EJ, et al. Clin Pharmacokinet. 2016 Dec;55(12):1471-1494. doi: 10.1007/s40262-016-0407-2. Clin Pharmacokinet. 2016. PMID: 27317413 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Search Page

Filters